Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, Arakelyan N, Culine S; GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales). Oudard S, et al. Among authors: escudier b. J Urol. 2007 May;177(5):1698-702. doi: 10.1016/j.juro.2007.01.063. J Urol. 2007. PMID: 17437788 Clinical Trial.
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Escudier B, Choueiri TK, Oudard S, Szczylik C, Négrier S, Ravaud A, Chevreau C, Venner P, Champagne P, Croteau D, Dupont E, Hariton C, Bukowski RM. Escudier B, et al. J Urol. 2007 Nov;178(5):1901-5. doi: 10.1016/j.juro.2007.07.035. Epub 2007 Sep 17. J Urol. 2007. PMID: 17868728 Clinical Trial.
Metastatic renal cell carcinoma management.
Heldwein FL, Escudier B, Smyth G, Souto CA, Vallancien G. Heldwein FL, et al. Among authors: escudier b. Int Braz J Urol. 2009 May-Jun;35(3):256-70. doi: 10.1590/s1677-55382009000300002. Int Braz J Urol. 2009. PMID: 19538761 Free article. Review.
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors.
Malouf GG, Camparo P, Molinié V, Dedet G, Oudard S, Schleiermacher G, Theodore C, Dutcher J, Billemont B, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Escudier B. Malouf GG, et al. Among authors: escudier b. J Urol. 2011 Jan;185(1):24-9. doi: 10.1016/j.juro.2010.08.092. Epub 2010 Nov 12. J Urol. 2011. PMID: 21074195
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
Neuzillet Y, Tillou X, Mathieu R, Long JA, Gigante M, Paparel P, Poissonnier L, Baumert H, Escudier B, Lang H, Rioux-Leclercq N, Bigot P, Bernhard JC, Albiges L, Bastien L, Petit J, Saint F, Bruyere F, Boutin JM, Brichart N, Karam G, Branchereau J, Ferriere JM, Wallerand H, Barbet S, Elkentaoui H, Hubert J, Feuillu B, Theveniaud PE, Villers A, Zini L, Descazeaux A, Roupret M, Barrou B, Fehri K, Lebret T, Tostain J, Terrier JE, Terrier N, Martin L, Dugardin F, Galliot I, Staerman F, Azemar MD, Irani J, Tisserand B, Timsit MO, Sallusto F, Rischmann P, Guy L, Valeri A, Deruelle C, Azzouzi AR, Chautard D, Mejean A, Salomon L, Rigaud J, Pfister C, Soulié M, Kleinclauss F, Badet L, Patard JJ; Comité de Transplantation de l'Association Française d'Urologie; Comité de Cancérologie de l'Association Française d'Urologie. Neuzillet Y, et al. Among authors: escudier b. Eur Urol. 2011 Aug;60(2):366-73. doi: 10.1016/j.eururo.2011.02.035. Epub 2011 Mar 2. Eur Urol. 2011. PMID: 21377780
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
Bigot P, Fardoun T, Bernhard JC, Xylinas E, Berger J, Rouprêt M, Beauval JB, Lagabrielle S, Lebdai S, Ammi M, Baumert H, Escudier B, Grenier N, Hétet JF, Long JA, Paparel P, Rioux-Leclercq N, Soulié M, Azzouzi AR, Bensalah K, Patard JJ. Bigot P, et al. Among authors: escudier b. World J Urol. 2014 Feb;32(1):109-14. doi: 10.1007/s00345-013-1088-1. Epub 2013 Apr 27. World J Urol. 2014. PMID: 23624719
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, Loriot Y, Fizazi K, Escudier B. Ferté C, et al. Among authors: escudier b. Eur Urol. 2014 Apr;65(4):713-20. doi: 10.1016/j.eururo.2013.08.010. Epub 2013 Aug 15. Eur Urol. 2014. PMID: 23993162 Clinical Trial.
552 results